Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.
2025
Earnings, Q4 FY2025
Feb 4, 2026
FY25 revenue beats expectations; cash runway secured through December 2026.
Earnings, H1 FY2025
Sep 30, 2025
Revenue and repeat sales fell short, triggering a strategic review and urgent cash preservation.
2024
Earnings, H2 FY2024
Annual
Apr 15, 2025
2024 saw maiden profit, strong Eroxon rollout, and pipeline progress, but sales guidance lowered.
Earnings, H1 FY2024
Sep 10, 2024
Achieved maiden profit and 300% revenue growth, with major U.S. launch set for October.